Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice
In mice, alcohol cut the efficacy of anti-PD-1 immunotherapy by roughly 50%, suppressing tumor-infiltrating and memory T cells while boosting TIGIT-carrying ones. Blocking TIGIT restored the response. The post Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice appeared first on GEN - Genetic Engineering and Biotechnology News .
A recent study conducted by researchers at the University of North Carolina at Chapel Hill has found that regular alcohol consumption may reduce the effectiveness of cancer immunotherapy, specifically anti-PD-1 antibodies. Published in Science Signaling, the research indicates that alcohol use may weaken some T cells while enhancing others, negatively impacting anti-tumor immunity.
The study involved administering moderate-to-heavy ethanol to mouse models of lung and bladder cancer, combined with anti-PD-1 treatment. The findings showed that alcohol reduced the efficacy of immunotherapy by about 50% and increased tumor recurrence. In mice with MB49 bladder tumors, alcohol decreased the number of tumor-infiltrating T cells, shifted CD4+ T cells towards a T helper 17 profile, reduced tissue-resident memory T cells, and increased the proportion of T cells expressing TIGIT, an alternative immune checkpoint receptor.
The researchers also analyzed a cohort of patients with various cancers who had received immune checkpoint inhibitors. Patients who reported drinking eight or more drinks a week had poorer survival after starting treatment, particularly in lung cancer patients. The study suggests that targeting specific changes caused by alcohol consumption, such as TIGIT and SREBP-mediated lipid signaling, could help restore the effectiveness of anti-PD-1 treatment.
The authors recommend incorporating patients' alcohol use into cancer databases to better understand its impact on various therapies, such as CAR T cell therapy, chemotherapy, and radiation across multiple cancers.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.